Abstract:ABSTRACT To combat the global burden of malaria, development of new drugs to replace or complement current therapies is urgently required. Here, we show that the compound MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to inhibition of end-stage hemoglobin digestion in asexual parasites. MMV1557817 can kill sexual-stage P. falciparum , is active against murine malaria, and does not show any shift in activity against a panel of parasites resistant to other antimalarials. MMV1557817 -resistant P. falciparum exhibited a slow growth rate that was quickly outcompeted by wild-type parasites and were sensitized to the current clinical drug, artemisinin. Overall, these results confirm MMV1557817 as a lead compound for further drug development and highlights the potential of dual inhibition of M1 and M17 as an effective multi-species drug-targeting strategy. IMPORTANCE Each year, malaria infects approximately 240 million people and causes over 600,000 deaths, mostly in children under 5 years of age. For the past decade, artemisinin-based combination therapies have been recommended by the World Health Organization as the standard malaria treatment worldwide. Their widespread use has led to the development of artemisinin resistance in the form of delayed parasite clearance, alongside the rise of partner drug resistance. There is an urgent need to develop and deploy new antimalarial agents with novel targets and mechanisms of action. Here, we report a new and potent antimalarial compound, known as MMV1557817 , and show that it targets multiple stages of the malaria parasite lifecycle, is active in a preliminary mouse malaria model, and has a novel mechanism of action. Excitingly, resistance to MMV15578117 appears to be self-limiting, suggesting that development of the compound may provide a new class of antimalarial.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop new anti - malaria drugs to address the current drug - resistance issues of anti - malaria drugs such as artemisinin - based combination therapies (ACTs). Specifically, the researchers have discovered a new compound named MMV1557817. This compound can simultaneously inhibit two aminopeptidases M1 and M17 in the malaria parasite (*Plasmodium* spp.), thereby leading to the inhibition of late - stage hemoglobin digestion and being active against multiple life - cycle stages of the malaria parasite. In addition, this compound has shown activity in a preliminary mouse malaria model and has a new mechanism of action. Excitingly, the resistance to MMV1557817 seems to be self - limiting, indicating that this compound may become a new class of anti - malaria drugs. ### Research Background Every year, malaria infects approximately 240 million people and causes more than 600,000 deaths, most of which are children under 5 years old. Over the past decade, the World Health Organization (WHO) has recommended the use of artemisinin - based combination therapies (ACTs) as the global standard for malaria treatment. However, the widespread use of these drugs has led to the emergence of partial artemisinin resistance, especially in high - prevalence areas in Southeast Asia and Africa. The emergence of this resistance threatens the malaria elimination goals set by the WHO, so there is an urgent need to develop new anti - malaria drugs with new targets and mechanisms of action. ### Research Objectives 1. **Develop new anti - malaria compounds**: The researchers aim to develop a new anti - malaria compound that can effectively inhibit M1 and M17 aminopeptidases in the malaria parasite. 2. **Verify multi - species targeting strategies**: By simultaneously inhibiting M1 and M17 aminopeptidases, the researchers hope to verify whether this strategy can be an effective multi - species drug - targeting method. 3. **Evaluate the activity and safety of the compound**: The researchers evaluated the activity of MMV1557817 under laboratory conditions, as well as its preliminary efficacy and safety in a mouse model. ### Main Findings - **Selective inhibition**: MMV1557817 is a selective, nanomolar - level inhibitor that can simultaneously inhibit M1 and M17 aminopeptidases in the malaria parasite. - **Multi - stage activity**: This compound is not only effective against the asexual stage of the malaria parasite, but can also kill the sexual stage of *P. falciparum*, and has shown activity in a mouse malaria model. - **Resistance characteristics**: *P. falciparum* that is resistant to MMV1557817 has a slower growth rate, is easily eliminated by wild - type parasites, and is sensitive to the current clinical drug artemisinin. ### Conclusion Overall, these results confirm MMV1557817 as a candidate compound for further drug development and emphasize the potential of simultaneously inhibiting M1 and M17 aminopeptidases as a multi - species drug - targeting strategy.

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box

Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization

Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

Identification of Potent and Reversible Piperidine Carboxamides That Are Species-Selective Orally Active Proteasome Inhibitors to Treat Malaria

High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of Plasmodium falciparum

Genetic and chemical validation of Plasmodium falciparum aminopeptidase Pf A-M17 as a drug target in the hemoglobin digestion pathway

Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission

A novel multiple-stage antimalarial agent that inhibits protein synthesis

The Cytoplasmic Prolyl-Trna Synthetase of the Malaria Parasite is a Dual-Stage Target of Febrifugine and Its Analogs.

Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome

Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein

Functional Phenotyping of MMV Pandemic Response Box Identifies Stage-specific inhibitors Against Blood stage Plasmodium

The Cytoplasmic Prolyl-tRNA Synthetase of the Malaria Parasite is a Dual-Stage Target for Drug Development

Replenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage Plasmodium falciparum, using a nano luciferase reporter read-out

Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance

Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets

QSAR-Driven Design and Discovery of Novel Compounds With Antiplasmodial and Transmission Blocking Activities

Design and Synthesis of Small Molecular Dual Inhibitor of Falcipain-2 and Dihydrofolate Reductase As Antimalarial Agent

Dual-pharmacophore artezomibs hijack the <i>Plasmodium</i> eubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance